The research areas in the Sinko Group include drug delivery and targeting with an emphasis on AIDS, cancer, and chemical counterterrorism, biomaterials, hydrogels and nanocarriers, mechanism-based pharmacokinetics and biopharmaceutics; transport and metabolism, and bioavailability.
The group is organized into therapeutic areas focusing on AIDS, cancer, and chemical counter-terrorism. Drug delivery at the molecular scale (i.e., nano) using biodegradable and biocompatible polymer platforms is a central theme of the group. Current research is funded by grants from the NIH/NIAID (R37 AI51214)NIH/NCI (R01 CA155061), and NIH/NIAMS (U54 AR055073), .
The scope of all current projects includes a molecular mechanistic component, chemical design and synthesis, and biological and efficacy characterization (in vitro, in situ, and in vivo) with an emphasis on translation from concept to the clinic.
Current projects: click here. AIDS: (1) eradication of HIV disease using nanocarriers that target T-cells and macrophages and enhance brain uptake (AI51214, PI = Sinko); and (2) prevention of HIV transmission using nanocarrier-based foams to prevent permanent HIV infectoin following colorectal viral exposure (AI11776, PI = Sinko)). Cancer: (1) Non small cell lung cancer & metastasis treatment (CA155061, PI=Sinko); (2) treatment diagnosis, treatment, and prevention of invasive breast cancer; (3) identification and treatment of micrometastases; and (4) induction of apoptosis. Chemical Counter-terrorism (AR055073): (1) spray-on/pour-on dermal delivery system for vesicant-induced wounds; (2) injectable aggregated nanogel particles for pulmonary delivery; and (3) PEG nanocarrier hydrogels for ocular delivery of MMP inhibitors. More information on the Rutgers University CounterACT Center of Excellence can be found [here].